Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$4.18 ▲ +0.01
(+0.24%)
MKT CAP: $191.6M • VOL: 66.1K
52W L $2 52W H $6
FOCL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $70.5M | $69.4M |
| YoY Revenue Growth % | +1.6% | — |
| Gross Profit | $30.0M | $28.7M |
| Gross Margin % | 42.5% | 41.4% |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$24.7M | -$22.2M |
| Operating Margin % | -35.0% | -32.0% |
| Net Income (GAAP) | -$29.2M | -$20.6M |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$16.4M | -$14.7M |
| Capital Expenditures (CapEx) | — | — |
| Free Cash Flow (FCF) | -$16.4M | -$14.7M |
| FCF Margin % | -23.3% | -21.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $20.5M | $31.0M |
| Total Debt (Short + Long Term) | $15.9M | $2.2M |
| Total Stockholders' Equity | $19.4M | $42.5M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FOCL.